242 related articles for article (PubMed ID: 33694182)
21. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
22. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines.
Lin MF; Meng TC; Rao PS; Chang C; Schonthal AH; Lin FF
J Biol Chem; 1998 Mar; 273(10):5939-47. PubMed ID: 9488733
[TBL] [Abstract][Full Text] [Related]
23. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
[TBL] [Abstract][Full Text] [Related]
24. A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells.
Kizu R; Okamura K; Toriba A; Kakishima H; Mizokami A; Burnstein KL; Hayakawa K
Arch Toxicol; 2003 Jun; 77(6):335-43. PubMed ID: 12799773
[TBL] [Abstract][Full Text] [Related]
25. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
Rivest P; Renaud M; Sanderson JT
Chem Biol Interact; 2011 Feb; 189(3):177-85. PubMed ID: 21111724
[TBL] [Abstract][Full Text] [Related]
26. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
Kim HJ; Park YI; Dong MS
Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
[TBL] [Abstract][Full Text] [Related]
27. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
28. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY
Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional suppression of androgen receptor by 18β-glycyrrhetinic acid in LNCaP human prostate cancer cells.
Sun Y; Jiang M; Park PH; Song K
Arch Pharm Res; 2020 Apr; 43(4):433-448. PubMed ID: 32219716
[TBL] [Abstract][Full Text] [Related]
30. Intracellular distribution of vinclozolin and its metabolites differently affects 5α-dihydrotestosterone (DHT)-induced PSA secretion in LNCaP cells.
Marcoccia D; Smeriglio A; Mantovani A; Trombetta D; Lorenzetti S
Reprod Toxicol; 2022 Aug; 111():83-91. PubMed ID: 35595151
[TBL] [Abstract][Full Text] [Related]
31. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
33. Neural androgen receptor regulation: effects of androgen and antiandrogen.
Lu S; Simon NG; Wang Y; Hu S
J Neurobiol; 1999 Dec; 41(4):505-12. PubMed ID: 10590174
[TBL] [Abstract][Full Text] [Related]
34. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
35. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
36. Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer Cells.
Fajardo AM; MacKenzie DA; Olguin SL; Scariano JK; Rabinowitz I; Thompson TA
PLoS One; 2016; 11(3):e0151525. PubMed ID: 26986969
[TBL] [Abstract][Full Text] [Related]
37. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways.
Sadar MD
J Biol Chem; 1999 Mar; 274(12):7777-83. PubMed ID: 10075669
[TBL] [Abstract][Full Text] [Related]
38. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
39. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
